Clark R E, Marbarger J P, West P N, Spratt J A, Florence J M, Roper C L, Ferguson T B, Weldon C S
J Thorac Cardiovasc Surg. 1980 Nov;80(5):696-701.
An 8 year experience with a prospective treatment program for patients with myasthenia gravis is reviewed with particular focus on the results in patients less than 35 years of age. Twenty myasthenic young adults with an average age of 24 years and a duration of symptoms of 22 months, excluding two with the juvenile form, had thymectomy followed by short-term anticholinesterase and long-term prednisone therapy. All of the 18 patients with a short duration of symptoms are in markedly improved condition and 61% of them are in remission after a mean postoperative period of 32 months. The longest follow-up period is 7.3 years. Two patients have mild improvement. There was no correlation between thymic disease and clinical result. Complete en bloc extirpation of all thymic and adjacent tissue through a median sternotomy is advocated. The patients were treated postoperatively with prednisone, 100 mg/day, a regimen which gradually is changed to every other day medication and finally a gradual reduction of dosage. There have been no operative or late deaths and no serious complications of therapy. The effects have been long lasting, with not a single instance of significant recurrence of symptoms of myasthenia gravis 6 months after thymectomy.
回顾了一项针对重症肌无力患者的前瞻性治疗计划的8年经验,特别关注35岁以下患者的治疗结果。20名平均年龄24岁、症状持续22个月的重症肌无力青年成人(不包括两名青少年型患者)接受了胸腺切除术,随后进行短期抗胆碱酯酶和长期泼尼松治疗。18名症状持续时间较短的患者病情均明显改善,平均术后32个月,其中61%的患者病情缓解。最长随访期为7.3年。两名患者有轻微改善。胸腺疾病与临床结果之间无相关性。主张通过正中胸骨切开术整块完整切除所有胸腺及相邻组织。术后患者接受泼尼松治疗,剂量为100毫克/天,该方案逐渐改为隔日用药,最后逐渐减少剂量。无手术死亡或晚期死亡病例,也无严重治疗并发症。治疗效果持久,胸腺切除术后6个月无1例重症肌无力症状显著复发。